CL2017000915A1 - Uso de ácido neridrónico o de su sal para el tratamiento de la osteoatrosis - Google Patents
Uso de ácido neridrónico o de su sal para el tratamiento de la osteoatrosisInfo
- Publication number
- CL2017000915A1 CL2017000915A1 CL2017000915A CL2017000915A CL2017000915A1 CL 2017000915 A1 CL2017000915 A1 CL 2017000915A1 CL 2017000915 A CL2017000915 A CL 2017000915A CL 2017000915 A CL2017000915 A CL 2017000915A CL 2017000915 A1 CL2017000915 A1 CL 2017000915A1
- Authority
- CL
- Chile
- Prior art keywords
- salt
- treatment
- neridronic acid
- osteoatrosis
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
<p>SE DESCRIBE EL USO DEL ÁCIDO NERIDRÓNICO O UNA SAL DEL MISMO EN EL TRATAMIENTO DE LA OSTEOARTRITIS. EN PARTICULAR, SE HA DEMOSTRADO QUE EL ACIDO NERIDRÓNICO O UNA SAL DEL MISMO ES CAPAZ DE REDUCIR SIGNIFICATIVAMENTE LOS SÍNTOMAS DE LA OSTEOARTRITIS, TALES COMO EL DOLOR Y LAS DISCAPACIDADES FÍSICAS Y DE MOVILIDAD, AL IGUAL QUE LAS LESIONES DE LA MEDULA ÓSEA SUBCONDRAL SUBVACENTES A LA APARICIÓN DE ESTOS SÍNTOMAS.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20141794 | 2014-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000915A1 true CL2017000915A1 (es) | 2017-11-10 |
Family
ID=51904075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000915A CL2017000915A1 (es) | 2014-10-15 | 2017-04-12 | Uso de ácido neridrónico o de su sal para el tratamiento de la osteoatrosis |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20170209470A1 (es) |
| EP (1) | EP3206694B1 (es) |
| JP (1) | JP6839076B2 (es) |
| KR (1) | KR102591084B1 (es) |
| CN (2) | CN106794190A (es) |
| AU (1) | AU2015332060B2 (es) |
| BR (1) | BR112017006989A2 (es) |
| CA (1) | CA2963066C (es) |
| CL (1) | CL2017000915A1 (es) |
| CO (1) | CO2017003561A2 (es) |
| CY (1) | CY1123420T1 (es) |
| DK (1) | DK3206694T3 (es) |
| DO (1) | DOP2017000096A (es) |
| EA (1) | EA033191B1 (es) |
| EC (1) | ECSP17023093A (es) |
| ES (1) | ES2819186T3 (es) |
| HR (1) | HRP20201475T1 (es) |
| HU (1) | HUE052088T2 (es) |
| IL (1) | IL251421B (es) |
| LT (1) | LT3206694T (es) |
| MX (1) | MX2017004826A (es) |
| MY (1) | MY191481A (es) |
| NZ (1) | NZ730853A (es) |
| PE (1) | PE20170699A1 (es) |
| PH (1) | PH12017500659A1 (es) |
| PL (1) | PL3206694T3 (es) |
| PT (1) | PT3206694T (es) |
| RS (1) | RS60868B1 (es) |
| SG (1) | SG11201702574XA (es) |
| SI (1) | SI3206694T1 (es) |
| TN (1) | TN2017000095A1 (es) |
| WO (1) | WO2016059594A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190328755A1 (en) * | 2018-04-30 | 2019-10-31 | Grunenthal Gmbh | Methods of treating complex regional pain syndrome (crps) or symptoms comprising administration of neridronic acid |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20040218A1 (it) * | 2004-02-10 | 2004-05-10 | Abiogen Pharma Spa | Uso di neridronato sodico per promuovere la neoformazione ossea |
| AU2005240107A1 (en) * | 2004-05-06 | 2005-11-17 | Merck & Co., Inc. | Methods for treating arthritic conditions in dogs |
| CN101405007A (zh) * | 2006-02-06 | 2009-04-08 | 赛普拉斯生物科学公司 | 包含二膦酸盐和抗叶酸剂的组合物 |
| US20070191315A1 (en) * | 2006-02-16 | 2007-08-16 | Bengt Bergstrom | Method for administering ibandronate |
-
2015
- 2015-10-15 RS RS20201089A patent/RS60868B1/sr unknown
- 2015-10-15 EP EP15797421.3A patent/EP3206694B1/en active Active
- 2015-10-15 KR KR1020177010305A patent/KR102591084B1/ko active IP Right Grant
- 2015-10-15 PL PL15797421T patent/PL3206694T3/pl unknown
- 2015-10-15 HU HUE15797421A patent/HUE052088T2/hu unknown
- 2015-10-15 TN TN2017000095A patent/TN2017000095A1/en unknown
- 2015-10-15 PE PE2017000541A patent/PE20170699A1/es unknown
- 2015-10-15 ES ES15797421T patent/ES2819186T3/es active Active
- 2015-10-15 CA CA2963066A patent/CA2963066C/en active Active
- 2015-10-15 US US15/514,651 patent/US20170209470A1/en not_active Abandoned
- 2015-10-15 JP JP2017519665A patent/JP6839076B2/ja active Active
- 2015-10-15 BR BR112017006989-0A patent/BR112017006989A2/pt not_active Application Discontinuation
- 2015-10-15 LT LTEP15797421.3T patent/LT3206694T/lt unknown
- 2015-10-15 AU AU2015332060A patent/AU2015332060B2/en active Active
- 2015-10-15 SG SG11201702574XA patent/SG11201702574XA/en unknown
- 2015-10-15 CN CN201580055571.8A patent/CN106794190A/zh active Pending
- 2015-10-15 DK DK15797421.3T patent/DK3206694T3/da active
- 2015-10-15 EA EA201790531A patent/EA033191B1/ru not_active IP Right Cessation
- 2015-10-15 MX MX2017004826A patent/MX2017004826A/es unknown
- 2015-10-15 NZ NZ730853A patent/NZ730853A/en unknown
- 2015-10-15 CN CN202010813830.1A patent/CN111939164A/zh active Pending
- 2015-10-15 SI SI201531345T patent/SI3206694T1/sl unknown
- 2015-10-15 MY MYPI2017701067A patent/MY191481A/en unknown
- 2015-10-15 WO PCT/IB2015/057929 patent/WO2016059594A1/en active Application Filing
- 2015-10-15 PT PT157974213T patent/PT3206694T/pt unknown
-
2017
- 2017-03-27 IL IL251421A patent/IL251421B/en unknown
- 2017-04-07 PH PH12017500659A patent/PH12017500659A1/en unknown
- 2017-04-10 DO DO2017000096A patent/DOP2017000096A/es unknown
- 2017-04-12 CL CL2017000915A patent/CL2017000915A1/es unknown
- 2017-04-12 CO CONC2017/0003561A patent/CO2017003561A2/es unknown
- 2017-04-13 EC ECIEPI201723093A patent/ECSP17023093A/es unknown
-
2020
- 2020-09-15 CY CY20201100872T patent/CY1123420T1/el unknown
- 2020-09-16 HR HRP20201475TT patent/HRP20201475T1/hr unknown
-
2023
- 2023-03-29 US US18/192,094 patent/US20230233585A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| DOP2015000246A (es) | Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares | |
| CL2016002971A1 (es) | Combinación. | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CL2015002546A1 (es) | Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos | |
| BR112016021034A2 (pt) | Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit | |
| CO2017005968A2 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| SV2016005301A (es) | Nuevos compuestos macrocíclicos | |
| CR20160133A (es) | Derivados de fenilalanina sustituidos | |
| DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| GT201700016A (es) | [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
| DOP2017000014A (es) | Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo | |
| UY35745A (es) | Derivados sustituidos de fenilalanina | |
| UY35602A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| CL2016000583A1 (es) | Mandelato de atrasentan; formas cristalinas anhidra e hidratada de s-mandelato, y anhidra de r-mandelato de atrasentan; composición farmacéutica que las comprende; y su uso para tratar una enfermedad renal crónica. | |
| CO2018012180A2 (es) | Métodos de tratamiento para enfermedades colestásicas y fibróticas | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
| ES1178860Y (es) | Atuendo para facilitar la utilizacion de piedras para chakras | |
| UY35610A (es) | Derivados de prodroga de triazolpiridinas sustituidas | |
| CL2017000915A1 (es) | Uso de ácido neridrónico o de su sal para el tratamiento de la osteoatrosis | |
| EP3116528A4 (en) | Adjuvant therapy to standard of care (soc) diuretic treatment |